Full-Time

Senior Manufacturing Engineer

Posted on 5/16/2026

Insulet Corporation

Insulet Corporation

5,001-10,000 employees

Develops tubeless insulin pumps and pods

Compensation Overview

$94.7k - $142.1k/yr

+ Incentive Compensation

Acton, MA, USA

In Person

Requires on-site office/plant/lab work.

Category
Mechanical Engineering (1)
Required Skills
CAD
Word/Pages/Docs
Assembly
Data Analysis
Excel/Numbers/Sheets
PowerPoint/Keynote/Slides
Requirements
  • BS in Mechanical, Industrial, or equivalent field with 5+ years of manufacturing experience, preferably in a medical device or highly regulated environment
  • OR MS in Mechanical, Industrial, Electrical Engineering, or equivalent with 3-5 years of manufacturing experience, preferably in a medical device or highly regulated environment
  • Hands-on experience in setup and operation of automated production equipment
  • Advanced proficiency in MS Office (MS Word, Excel, Power Point, Outlook) and data analytics tools
  • Process oriented and uses data to make decisions
  • Demonstrated success using problem solving methodologies such as A3, PDCA, DMAIC, etc.
  • Ability to fulfill job responsibilities in a fast-paced/high-volume production environment
  • Mechanical aptitude, technical ability, ability to read and understand technical drawings and manuals
  • Hands-on technical ability with assembly methodologies including locational methods, assembly setup, pneumatic actuators, servo motors, limit switches, sensors, robotics, etc.
Responsibilities
  • Accountable to driving maintenance process improvements in support of Insulet’s primary manufacturing objectives: Best Quality, Best Service, Best Cost.
  • Autonomously interprets data to drive plant decision making and prioritization of reliability efforts.
  • Plan, execute, and manage efficiency improvement projects.
  • Develop and implement process controls to stabilize and sustain equipment reliability.
  • Develop and deliver training to build the capability of the plant engineering and operations teams as part of continuous improvement efforts.
  • Independently maintains and publishes operating scorecard to track and trend projects/improvements.
  • Create and modify preventive maintenance tasks and work plans to move unplanned emergency events to planned maintenance events.
  • Maintain direct hands-on interaction with the manufacturing equipment including station set-up and troubleshooting using hand tools, measurement tools, machine documents, specialty gages, and high-speed filming equipment
  • Provide input and support for technology transfer and equipment design reviews.
  • Ensure compliance with safety rules, quality policies, and employee guidelines
  • Maintain a cGMP compliant environment and operate within FDA guidelines for 21CFR820 manufacturing.
  • Serves as back-up Maintenance Operations Manager. Off-shift support may be required.
  • Perform other duties as required
Desired Qualifications
  • Experience with SOLIDWORKS or AutoCAD.
  • Technical knowledge of cam driven linkages, discrete component assembly, and automation
  • Familiarity with machine user interfaces (HMIs / GUIs)
  • Familiarity working within cGMP guidelines and ISO 13485/21CFR820 regulations.
  • Experience working in a regulated industry, in particular consumable products.
  • Have strong interpersonal and communication skills
  • Excellent attention to detail, organizational skills, and rigorous process discipline
  • Thirst for knowledge and intense curiosity

Insulet Corporation designs, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. Its flagship product, the Omnipod, is a tubeless, waterproof insulin pump that delivers a continuous subcutaneous infusion of insulin through disposable pods controlled by a personal diabetes manager. The system works by wearing a pod on the body, programming insulin delivery via the PDM (or a connected device), and, in newer versions like Omnipod 5, integrating with continuous glucose monitors to automatically adjust insulin delivery. Compared with many competitors, Insulet emphasizes a tubeless, wireless pump with a disposable pod ecosystem, adding automated insulin delivery features and CGM integration to streamline diabetes care. The company aims to simplify and improve diabetes management, offering a convenient and discreet insulin delivery method to reduce the burden of daily diabetes care for users around the world.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

Acton, Massachusetts

Founded

2000

Simplify Jobs

Simplify's Take

What believers are saying

  • International Omnipod 5 sales rose 45% in Q1 2026.
  • Libre 3 Plus integration targets 450,000 existing U.S. users.
  • EVOLVE’s type 2 closed-loop program supports a 2027 510(k) filing.

What critics are saying

  • March 2026 recall involved tubing tears, 29 serious injuries, and Class I status.
  • Insulet reported $12 million recall costs in Q1, pressuring margins through 2026.
  • Medtronic, Tandem, and Abbott can exploit Omnipod’s technology gap until 2027.

What makes Insulet Corporation unique

  • Omnipod 5 is the only widely used tubeless automated insulin delivery system.
  • Insulet combines disposable pods with CGM interoperability and smartphone-driven dosing.
  • Its direct-to-patient model supports recurring pod revenue and frequent user touchpoints.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Insulet Corporation who can refer or advise you

Benefits

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Apr 9th, 2026
Analysts see 75% upside on Insulet despite 11% drop in 2026

Insulet Corporation has a consensus analyst price target of $360, implying 75% upside, with over 90% of analysts maintaining bullish ratings as of 6 April 2026. However, shares have fallen over 11% year-to-date and hit a 52-week low of $202.44 on 2 April, down more than 16% from a year earlier. The medical device company, which manufactures the Omnipod tubeless insulin pump, appointed Mike Panos as executive vice president and chief commercial officer on 30 March to strengthen commercial capabilities. CEO Ashley McEvoy cited significant growth opportunities driven by expanding global adoption of automated insulin delivery systems as the standard of care for both type 1 and type 2 diabetes.

Massachusetts Life Sciences Center
Apr 2nd, 2026
MLSC partners highlight innovation and access at MassMEDIC Symposium and Gala.

MLSC partners highlight innovation and access at MassMEDIC Symposium and Gala. * April 2, 2026 As a proud sponsor of the 2026 MassMEDIC Medtech Impact Symposium and Gala, the Massachusetts Life Sciences Center (MLSC) joined partners and awardees from across the life sciences community to showcase the collaborations and investments driving meaningful progress for patients on a global scale. The Symposium brought together ecosystem leaders to explore how the medtech industry can deliver better outcomes while managing costs and sustaining innovation. In the afternoon, the Symposium shifted to three dynamic, concurrent panel tracks that examined the evolving landscape of healthcare delivery. Each panel featured practical, forward-looking dialogue focused on users, enabling technologies, and the accelerating shift in where care is delivered. MLSC-supported companies and partners played a key role throughout these discussions. Insulet Corporation, a crucial partner of the MLSC's Pathmaker program and a recipient of multiple Tax Incentive awards, participated in the panel, Everything, Everywhere, All the Time, which examined how healthcare systems balance quality, cost, and access in an increasingly complex environment. Panelists discussed how economic pressures, information gaps, and misaligned incentives continue to influence decision-making across the healthcare system. The MLSC has awarded Insulet with $16.3 million in tax incentives for the creation of 834 jobs. To date, the MLSC has invested $13.5 million in Pathmaker training organizations across Massachusetts, supporting more than 1,200 training opportunities and connecting graduates with 101 companies across the life sciences sector. Later in the afternoon, Gentuity, an industry partner of the MLSC's Bits to Bytes program, joined the panel, Talking Tech: Interventional Systems, where industry leaders shared perspectives on emerging trends and product innovation in interventional medical technologies. Through the Bits to Bytes program, the MLSC supports companies developing data-driven solutions that are advancing diagnosis and treatment. Over the past seven years, the program has awarded $27.6 million in capital funding to non-profit universities and academic medical centers who have partnered with companies like Gentuity, helping them bring cutting-edge technologies closer to patients. Rounding out the Symposium, MLSC COO Elizabeth Graham moderated a panel on assistive and autonomous technologies in clinical workflows, joined by leadership members of Johnson & Johnson MedTech - a longtime sponsor of the MLSC's Massachusetts Next Generation (MassNextGen) Initiative - and Robeauté, a company pioneering a new class of therapeutic microrobots. The discussion explored how tools such as surgical robotics, fully automated technologies, and critical care technologies are transforming care delivery, and examined the growing intersection of human expertise and automation. Since its founding in 2018, the MLSC's MassNextGen portfolio has grown to 39 companies, including 19 previous awardees that have raised seed or Series A financing. To date, MassNextGen companies have raised more than $401 million in follow-on funding. Reflecting the program's strong support for medical innovation, 28 percent of MassNextGen companies are developing novel technologies in the medical device space with the goal of improving patients' lives around the world. The day concluded with the Medtech Impact Gala, where the themes of the Symposium were reflected through powerful stories from patients and innovators. The evening celebrated the real-world impact of medical technology and recognized the individuals and organizations working to improve care around the world. The MLSC was proud to sponsor this event alongside several industry leaders and Tax Incentive awardees, including Insulet Corporation, Optikos, TransMedics, and ZOLL. Applications for several MLSC programs are now open, including Pathmaker, and both Impact Catalyst and MassNextGen with a deadline of June 12, 2026, at 1 p.m. EST. Announcements

Yahoo Finance
Apr 1st, 2026
Insulet appoints Mike Panos as CCO to drive global commercial strategy for diabetes tech platform

Insulet has appointed Mike Panos as Executive Vice President and Chief Commercial Officer to oversee its global commercial strategy and execution. The move follows strong quarterly results driven by the company's tubeless Pod insulin technology. Panos will lead global commercial strategy, market access and expansion into new geographies and patient segments. His appointment aligns with Insulet's focus on Omnipod 5 adoption and type 2 diabetes market penetration. The company's Q4 2025 revenue growth outpaced many patient monitoring peers, highlighting commercial momentum. Insulet's narrative projects $4.7 billion revenue and $716.9 million earnings by 2029, requiring 19.8% yearly revenue growth. However, investors face concentration risk around the Omnipod platform. Simply Wall St Community fair value estimates range widely, from $119.72 to $661,388.09, reflecting divergent views on the company's single-product strategy.

Yahoo Finance
Mar 31st, 2026
Insulet leads patient monitoring stocks with 31% revenue growth in Q4

Insulet reported Q4 revenues of $783.8 million, up 31.2% year on year, exceeding analysts' expectations by 2%. The diabetes care company, which develops tubeless insulin delivery systems through its Omnipod product line, delivered strong earnings with beats on both revenue and earnings per share estimates. The patient monitoring sector overall showed solid Q4 results, with the four tracked stocks beating revenue consensus estimates by 1.9% on average. However, next quarter's guidance came in 1.9% below expectations. Despite strong quarterly performance, Insulet shares have fallen 16% since reporting and currently trade at $206.93. The stock led the group in revenue growth but fell short of investor expectations, which may have been higher than published analyst projections.

Worcester Business Journal
Mar 30th, 2026
Insulet resurrects chief commercial officer role.

Insulet resurrects chief commercial officer role. March 30, 2026 Insulet has reinstated its chief commercial officer role after eliminating it three years ago. The Acton-based medical device manufacturer appointed Mike Panos to the resurrected position. Panos assumed his role as executive vice president, CCO of Insulet on Monday. In his new role, he will oversee the company's global commercial operations, including developing commercial strategies, growing market access, and supporting future growth, the company announced. Insulet develops and produces Omnipod, a line of tubeless insulin pumps for people with type 1 and type 2 diabetes. Panos' hiring comes as the company is implementing new strategies to strengthen its capabilities, said Insulet President and CEO Ashley McEvoy. Panos joins Insulet after working for three decades at Stryker, a Michigan-based medical device and equipment manufacturer. Panos began his tenure with the firm as a marketing associate in 1996, and most recently served as its leader, sales excellence, according to his LinkedIn profile. Panos graduated with his bachelor's and master's degrees from Boston College. Insulet originally eliminated its CCO position as part of an overall executive restructuring when Bret Christensen left the role to pursue another opportunity on May 5, 2023. Christensen's responsibilities were then split between Insulet's international general manager and U.S. general manager. As part of the reorganization, Insulet created a chief technology officer position and its first chief product and customer experience officer position. Mica Kanner-Mascolo is a staff writer at Worcester Business Journal, who primarily covers the healthcare, manufacturing, and higher education industries. - Digital Partners -